Shear effect on material induced blood cell activation by Chang, Xiaojian





presented to the University of Waterloo
in fulfilment of the
thesis requirement for the degree of
Master of Applied Science
in
Systems Design Engineering
Waterloo, Ontario, Canada, 2011
© Xiaojian Chang 2011
I hereby declare that I am the sole author of this thesis. This is a true copy of the thesis,
including any required final revisions, as accepted by my examiners.
I understand that my thesis may be made electronically available to the public.
ii
Abstract
Restenosis that occurs after stent implantation is a great threat to the quality of life of
patients with coronary artery diseases. Studies on thrombosis have revealed that platelet
is a primary component of blood clots, and leukocytes and other plasma proteins also
contribute to thrombus formation. However, the mechanism of material-induced activation,
especially with metallic materials, is currently not well understood and the effect of blood
flow on material-induced blood cell activation has not been well characterized.
In vitro static and flow experiments were performed to assess the effect of flow on blood
cell activation. Blood was taken from healthy donors. Two common stent metals, ST316L
and TiAl6V4, were used as test materials. In static experiments, blood was incubated
with metal disks at 37 ℃ for two hours. In flow experiments, blood was circulated in
flow chambers preloaded with or without metal wires at shear rates of 100 s−1, 500 s−1,
and 1500 s−1. Platelet and leukocyte activation, leukocyte-platelet aggregation, and tissue
factor expression on monocytes were measured by using a three-color FACSCalibur flow
cytometer. Fibrin deposition and blood cell adhesion on metal surfaces were evaluated by
scanning electron microscopy (SEM).
The results indicate that platelet and leukocyte activation under static condition was
low. TiAl6V4 metal disk induced relative lower platelet and leukocyte activation, albeit no
significant difference was found between control groups and the two metals tested. Shear
stress significantly enhanced platelet activation as measured by an increase in platelet
microparticle formation and platelet receptor CD61 expression. CD11b up-regulation,
leukocyte-platelet aggregates, and tissue factor (TF) expression increased at 100 s−1. How-
ever as shear rate increased, lower leukocyte activation was observed. TiAl6V4-induced
leukocyte activation was generally lower than that of ST316L. Significant fibrin deposition
and blood cell adhesion were observed on metal surfaces under static condition and with
iii
shear rate of 500 s−1. Adhesion significantly decreased with increasing shear rate to 1500
s−1.
The flow cytometry analysis results and SEM images demonstrated that materials with
different surface properties can induce different blood cell activation and adhesion after
incubation with blood. While shear may have an effect on blood cell activation, the effect
of biomaterials on cell activation under physiological shear conditions remains unclear.
Further studies are required to determine if an increase in biomaterial surface area will
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1.1 Coronary Artery Disease and Stents
Coronary artery disease (CAD) is one of the leading causes of death worldwide. It occurs
when the arteries that supply blood to the heart muscles become narrow. The inner walls
of arteries are normally smooth and flexible, allowing blood to flow through them easily.
However, fatty deposits or cholesterol plaques may build up on the inner walls of the
arteries, and thus narrow the blood vessel [1]. As a consequence, blood supply to heart
muscles reduces, resulting in the decrease of oxygen supply to the heart. About 90%
Canadians have at least one risk factor for heart disease. Factors can be as common as
smoking, drinking alcohol, physical inactivity, obesity, diabetes, high blood pressure, and
high blood cholesterol. Although the rate of coronary artery disease has steadily declined
over the past decade, it still accounts for 30% of death in Canada and costs tens of billions
of dollars every year in physician services, hospital costs, and decreased productivity [2].
The selection of CAD treatment varies with different factors, such as the severity and
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extent of CAD, overall heart function, and other medical conditions. For patients with
early stage CAD that does not limit blood flow, medication and lifestyle changes can help
to prevent progression. For patients with multiple areas of narrowed or blocked coronary
arteries, coronary artery bypass grafting (CABG) is a common procedure. CABG creates
a new path for blood to flow around the blockage in the stenotic arteries by grafting
blood vessels from elsewhere in the body. In other cases, balloon angioplasty and stenting
are applied. A balloon expands at the site of the stenotic artery to improve the blood
flow, which is often followed by stent placement. Stents are small metal wire mesh tubes.
They provide support to the artery wall and reduce the chance of blood vessel closing
subsequently. The narrowing of a blood vessel after stenting is known as restenosis [1].
Bare metal stents (BMS) were first introduced in the mid 1980s. They gained wide
clinical application throughout the 1990s. However, BMS were found to be a cause of stent
restenosis [3]. This is because blood cells preferably adhere at the site of vascular injury
induced during the stent placement, and smooth muscle cell proliferation results in throm-
bus formation in the stent. Drug-eluting stents (DES) preloaded with anti-proliferative or
anti-inflammatory drugs were developed to solve the restenosis of BMS [4]. In 2007, cases
of late thrombotic events and restenosis raised questions of the safety and efficacy of DES.
Both BMS and DES are currently available on the market, but no significant differences
in mortality rate at one year and beyond have been found [5]. Furthermore, the annual
incidence of death, myocardial infarction, and repeated revascularization caused by stent
implantation are more than 2% [6]. Late (between one month and one year) and very late
(after one year) DES and BMS thrombotic complications remain a common issue.
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1.2 Research Motivation and Objective
Researchers have noticed that some people get in-stent restenosis, while others receiving
the same stent implantation do not. They have been trying to find out the roles of blood
cells during contacting with stent materials and the mechanisms of blood cell activation,
and to design new therapeutic approaches to prevent failures following stent implantation.
As the main component of thrombus, platelets are thought to be the primary factor
that causes in-stent restenosis. However, blood-material contact actually involves the whole
blood circulation system. As shown in Figure 1.1, thrombosis involves not only platelet
activation, but also leukocyte activation, protein adsorption, and complement activation
[7]. Moreover, shear conditions in blood vessels also take part in blood cell activation [8].
Each factor, but also their interactions between each other, can be important. Therefore,







Figure 1.1: The interaction between blood cells and biomaterials [7].
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Stent material also plays an important role in the blood cell activation which is generally
characterized by events, such as an increase or decrease the number of membrane recep-
tors, the secretion of microparticles, and the formation of cell aggregates. Titanium alloys
and stainless steel (ST) alloys are widely used to fabricate stents because of their good
mechanical properties and outstanding corrosion resistance [9]. Material surface finishing
technologies can influence protein adsorption and cell-surface interaction [10]. Proper-
ties like surface roughness [10], chemical composition [11], and wettability [12] directly or
indirectly affect the interaction between blood cells and materials.
Although there has been continued interests in material hemocompatibility, the mech-
anism of blood-material interaction is still not well understood, especially among metal-
lic materials. In the present research, experiments have been conducted to understand
the mechanism of blood cell activation induced by incubation with different stent metals.
ST316L and titanium alloy TiAl6V4 have been selected and tested under both static and
flow conditions. Flow cytometry was used to analyze blood cell activities. Protein ad-
sorption and blood cell adhesion on the metal surfaces were assessed by scanning electron
microscope (SEM). Hemocompatibility of the two stent metals was compared, and the
shear effect on in-stent blood cell activation was studied.
1.3 Outline of Thesis
This thesis is organized as follows: Chapter 2 provides background on blood cells and
current knowledge on their functions in thrombus formation. Chapter 3 summarizes the
advantages and disadvantages of various flow models used in in vitro study. Chapter 4
describes the experimental methods and materials used in this work. Chapter 5 presents
the experimental results. Discussion, conclusions and recommendations for future work
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are presented in Chapter 6.
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Chapter 2
Blood Cells and Thrombosis
Blood delivers oxygen and nutrient to every cell in the body. It transports CO2 and other
waste products out from these cells. The prevention of excessive blood loss is one of the
important roles of blood vessels. The blood circulation system is able to rapidly detect
blood vessel damage and generate an effective thrombus plug to stop bleeding. Neverthe-
less, increased circulating blood volume and pressure, as required in larger animals, make
this function more significant and challenging.
The inner surface of blood vessel wall is the endothelium that acts as a selective barrier
between blood and the rest of vessel wall. The endothelium consists of a thin layer of
endothelial cells lining the entire circulatory system. They reduce the turbulence of blood
flow, allowing blood to be pumped farther [13]. Under normal conditions, endothelial
cells present a non-thrombogenic character by synthesizing and releasing two powerful
soluble inhibitors against platelets activation, nitric oxide and prostacyclin (PGI2), and by
expressing a thrombin inhibitor [14]. Their existence keeps blood vessel wall smooth and
reduce the chances of firm attachment of cells and proteins.
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Contact between blood and stent materials, and the trauma caused by stent placement
can induce the blood coagulation through the intrinsic (material surface contact activation)
and extrinsic (tissue factor) pathways respectively (Figure 2.1). The coagulation cascade is
an important part of hemostasis, and involves a series of proteolytic reactions resulting in
the formation of a fibrin clot which is one of the main components of blood clots [7,15,16].
Twelve factors (from factor I to XIII, except factor VI) are engaged in the process where
an inactive factor is enzymatically activated following surface contact or after proteolytic
cleavage by other enzymes; the newly activated factor then activates another inactive
precursor factor [7]. Both pathways converge on common pathway of activating factor X,
thrombin and fibrin.
Tissue factor (TF) is a key molecule during the activation of the extrinsic coagula-
tion cascade, leading to the fibrin formation. With antibody against to tissue factor can
inhibit fibrin deposition in thrombus [17]. Generally, tissue factor in normal blood is un-
detectable. Agents, such as inflammatory cytokines, virus infections, and thrombin, can
induce TF synthesis [18]. Moreover, monocytes can synthesize and express tissue factor af-
ter stimulation by LPS, and P-selectin, or high shear stress [19], and may lead to leukocyte
accumulation in areas of vascular injury associated with thrombosis and inflammation [20].
Blood contact with a material can induce TF expression on monocytes. A minimum of 60
min is needed for TF synthesis on monocytes [7]. In addition to monocytes, other sources
of tissue factor include the neutrophils [21], endothelium and blood plasma [22].
7
Figure 2.1: The intrinsic and extrinsic coagulation pathways. (Adapted from Adams,2009
[16])
2.1 Role of Platelets in Thrombus Formation
Platelets are disc-shaped anuclear cells with a diameter of 2-3 m, and produced by
megakaryocytes. They circulate at a concentration ranging from 200-500×106 cells/ml
for 5 to 9 days after leaving the bone marrow. On an intact and healthy endothelium,
platelets remain in their original and unactivated state. In most arteries, they appear to
migrate toward the vessel wall in a flow- and hematocrit-dependent manner because of the
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interaction between platelets and other blood cells. Platelet density near the vessel wall is
2 to 3 times higher than that in the center of the vessel [23].
Platelets play a crucial role in hemostasis and blood vessel repair through the formation
of blood clots. They also participate in the development of coronary artery diseases through
the pathological thrombus formation inside the blood vessel wall. Under normal conditions,
soluble agonists, such as von Willebrand factor (vWf), collagen and fibrinogen in plasma,
do not undergo significant interaction with platelets. However, platelets can rapidly adhere
to exposed subendothelium and smooth muscle cells by binding to collagen and vWf at the
site of blood vessel injury [7,24], as shown in Figure 2.2. Tissue factor (TF, CD142) from
exposed subendothelium promotes the formation of thrombin which is a potent platelet
activator (See Figure 2.2). Thrombin mediates the conversion of fibrinogen to fibrin that
also contributes to the formation of hemostatic plug and thrombus growth [24].
On activated endothelium or subendothelium, platelets roll, adhere, and form a mono-
layer of activated platelets [25]. With the presence of platelet activators or high shear
conditions, platelets become activated. Platelet activation can elicit a series of physiologic
responses, such as pseudopod formation and shape change, release of granules, biochemical
membrane alterations, initiation of aggregation and the formation of procoagulant platelet
microparticles (PMPs).
Once activation is initiated, platelets become more amorphous with projecting fingers,
and transform into dendritic and spread shape [26]. They secrete dense granules con-
taining ADP and  granules containing P-selecin, vWf and some other growth factors.
Membrane enzyme phospholipase A2 is activated, leading to the formation of Thrombox-
ane A2 (TXA2). Additional circulating platelets can thus be recruited to extend and
stabilize the hemostatic plug by binding to the activating factors, like ADP, TXA2, and
thrombin [7, 27, 28]. ADP acts via the G protein-coupled receptors, P2Y1 and P2Y2, to
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reinforce the platelet aggregation. TXA2 binds to the corresponding receptor to stimulate
the activation of new platelets and increases platelet aggregation (Figure 2.2). Moreover,
PMPs contribute to further platelet activation and aggregation, and help with the hemo-



















Figure 2.2: Platelet adhesion, activation and aggregation. Platelets adhere to the exposed
TF and vWf, resulting in the conformational change, and P-selectin expression. Activated
platelets release ADP, thrombin, and TXA2, leading to further platelets recruitment and
aggregation at the site of injury.
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2.1.1 Platelet receptors and agonists
An important platelet receptor is Glycoprotein Ib (GPIb), with a density of 25,000 copies
per platelet. It is associated with GPIX and GPV at a 2:2:1 ratio [30]. Conformational
changes of the GPIb molecule has been found to mediate the interaction between vWf
and GPIb-V-IX complex [7,30]. The initiation of platelet adhesion after vascular injury is
primarily mediated by the interaction between GPIb-V-IX receptor complex to vWf [28].
Under static or low shear conditions, platelet receptor GPVI and GPIa/IIa can bind to
collagen at the site of exposed subendothelium without the assistance of vWf. However,
vWf is required to mediate platelet adhesion in arterial circulation [31]. Platelets adhere
and decelerate until GPVI or integrin GPIIb/IIIa start to bind their respective ligands
and form permanent adhesion, spreading and aggregation. It also binds to the neutrophil
membrane receptor Mac-1 (also refer to as CD11b), P-selectin on activated platelets, and
endothelial cells [32].
GPIa/IIa (CD49b/CD29) presents at the level of 1000 copies per platelet, and is
required for platelet adhesion to collagen under static and flow conditions [33]. The inter-
action between GPVI and collagen can lead to shedding of membrane blebs (also referred
to as microparticles) into circulation, which provides procoagulant surfaces [28].
Glycoprotein IIb/IIIa (GPIIb/IIIa also refer to as CD41/61), is also known as inte-
grin IIb3. GPIIb/IIIa is the most abundant adhesive receptor on the platelet surface
at the density of about 50,000 on a resting platelet. It is also present in the  granules
of platelets. Upon activation,  granules translocate to the platelet membrane and in-
crease GPIIb/IIIa expression on platelets [33]. GPIIb/IIIa serves as a receptor for vWf,
fibronectin, and vitronectin, and can be recognized by specific antibodies, such as PAC-1
and anti-CD41/CD61 [7,33].
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GPIIb/IIIa remains inactive on resting platelets, with a low affinity binding site for fib-
rinogen. Activated GP IIb/IIIa mediates platelet recruitment as well as platelet-platelet
interactions. Conformational change after platelet stimulation leads to the expression of
high affinity GPIIb/IIIa binding site for soluble fibrinogen. The initial platelet adhesion
induced by GPIb-V-IX complex is reversible, while adhesion through GPIIb/IIIa can be
strengthened through binding to fibrinogen and thus become irreversible [28, 34, 35]. Fib-
rinogen contains a second binding site to GPIIb/IIIa or Mac-1 on leukocytes, leading to
the formation of platelet aggregates and platelet-leukocyte aggregates by cross-linking of
receptors on different cells. GPIIb/IIIa inhibitors, such as c7E3, can prevent platelet ag-
gregates formation [36]. Clinical studies have shown the efficacy of blocking GPIIb/IIIa to
reduce ischemic complications on CAD patients [37].
P-selectin (CD62p) is a platelet membrane glycoprotein and a component of the 
granules of resting platelets. It is only expressed on the platelet membrane surface after
activation-dependent release from the  granule (Figure 2.2). The P-selectin exposure on
platelet is partially regulated by vWf [38]. There are about 10,000 P-selectin molecules
expressed on an activated platelet [39]. P-selectin mediates the rolling of platelets on
endothelial cells [40] and the leukocyte-platelet aggregation through its leukocyte counter-
receptor, P-selectin Glycoprotein Ligand-1 (PSGL-1). It can be identified by flow cytome-
try, and is used as an important marker of platelet activation both in research and clinical
study [39,41].
2.1.2 Platelets under shear condition
Blood flow conditions can be quantified by shear rate (unit s−1). Shear rate refers to the
gradient of the velocity between two adjacent laminar flows. It is zero at the center of
the blood vessel, and maximum at the blood vessel wall (Figure 2.3) [42]. Sometimes,
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shear stress  is used to measure the blood flow, and it is proportional to shear rate
with a proportionality factor blood viscosity . In the human blood circulation system,
the physiological shear rate ranges from 20 to 2000 s−1. Accordingly, shear stress varies
from 1.4 to 60 dynes/cm2. In certain pathological flow conditions, shear rate can reach
105 s−1 [23, 43]. Typical time average values for healthy blood vessels are presented in
Table. 2.1.
High shear conditions, such as above 6000 s−1, are able to induce platelet activation
and aggregation in the absence of any other platelet activators. Platelets may experience
different shear rates at the sites of abrupt reduction in blood vessel cross-sectional area [44].
It has been reported that significant increase of PMPs formation can be detected under
pathological shear rate (10,500 s−1), but no significant formation of PMP was observed
at lower shear rates. This indicates that platelet activation proportionally correlates with
the magnitude of shear rate [43]. Boreda et al. further proved that platelet activation is







Figure 2.3: Shear rate definition and blood velocity profile within ideal blood vessel [42].
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Table 2.1: Characteristic value of flow parameters within the human vasculature [23]
Vessel Diameter (mm)  (s−1)  (dynes/cm2)
Ascending aorta 23-45 50-300 2-10
Femoral artery 5.0 300 11
Common carotid 5.9 250 8.9
Internal carotid 6.1 220 8
Left coronary 4.0 460 16
Right coronary 3.4 440 15
Small artery 0.3 1500 53
Arterioles 0.03 1900 60
Large vein 5-10 200 7
Studies have also shown that platelet aggregation preferentially occurs at regions of
flow disturbance where a shear acceleration zone is followed by a shear deceleration zone.
This means that shear gradient or certain geometric blood vessel shape may be necessary
for platelet aggregation formation. In vitro experiments have reported that under low
shear rate, no platelet aggregation occurred, while under shear rates from 1000 to 10,000
s−1, small transient aggregates formed through the development of membrane tethers.
Large rolling aggregates can be found at pathological shear rates over 100,000 s−1 [46]. To
14
mimic shear condition around the stenosis, experiments were performed using a backward-
facing step followed by an expansion zone [34]. Initial platelet recruitment occurred within
the zone of peak shear stress, and was followed by large platelet aggregation within the
shear deceleration zone. The result demonstrated that platelet aggregation appeared to be
dependent on the magnitude of the shear gradient and GPIb, but not on the soluble platelet
activators ADP, Thromboxane A2 and thrombin, soluble factors that would commonly be
present in a recirculation zone [34]. While the effect of shear and shear gradient has
been studied on platelet activation, most of these studies have not looked at the effect
of biomaterials and have often been performed under short contact times and/or in the
absence of red blood cells. To be able to design better biomaterials that will perform
adequately under shear conditions, it is thus important to study in vitro flow models that
could adequately assess material biocompatibility in blood.
2.2 Leukocytes and Thrombosis
There is increasing evidence indicating that leukocytes are involved in thrombosis [7, 19,
23, 47, 48]. Leukocytes consist of five different types of cells, which can be distinguished
by the presence of granules. Polymorphonuclear (PMN) leukocytes contain more than one
granule in their cytoplasm, and are composed of neutrophils, basophils and eosinophils.
Mononuclear leukocytes are characterized by the absence of granules in cytoplasm, and
include two subgroups, monocytes and lymphocytes.
Neutrophils, with a diameter of 8-15 m, are the most abundant leukocytes (50-70% of
all leukocytes). PMNs are the first line of defense as part of the innate immune response.
They phagocytize foreign cells, toxins and viruses. Monocyte is the largest leukocyte with
a diameter of 15-25 m. Circulating monocytes account for 3-9% of all leukocytes. With
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the assistance of fluorescent antibodies, they can be identified by the expression of large
amounts of lipopolysaccharide (LPS) receptor component, CD14 [49].
2.2.1 Activation, adhesion and aggregates
Upon activation, at the membrane level, leukocyte will respond by modulating the ex-
pression of certain receptors (down-regulation through shedding or up-regulation) and will
change in shape through pseudopod formation [50] (Figure 2.4). For example, L-selectin
exists on most leukocytes and sheds from their surface following cell activation [7,51]. Inhi-
bition of selectins can significantly reduce the leukocyte-platelet aggregation [52], leukocyte
adhesion, and fibrin deposition [19].
CD11b (or Mac-1) is up-regulated within minutes of exposure to proinflammatory sub-
stances such as Tumor necrosis factor (TNF)-, C5a, platelet-activating factor, and artifi-
cial material surfaces [7,53–56]. CD11b is one of the membrane protein subunits of integrin
M2, and can also bind to the inactive complement component iC3b. Leukocytes have
been shown to adhere onto artificial surfaces through the iC3b/CD11b complex. The
activation of CD11b integrin, which is partially dependent on the binding of P-selectin
to PSGL-1, can firm leukocyte-platelet adhesion through fibrinogen [19, 57]. Similarly, it
also mediates the firm attachment of leukocyte to the endothelial cell through its counter-
receptor ICAM-1. Activated monocytes synthesize and express tissue factor which can
initiate blood coagulation and mediates intracellular signaling events [21]. Studies on the
effects of neutrophils and monocytes in material induced thrombus formation have been
conducted as they are the main players defending against foreign materials [7].
Another marker for leukocyte activation is the formation of platelet-leukocyte aggre-
gates which can be formed when P-selectin expressed on platelets binds to PSGL-1 on
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leukocytes. Following activation, P-selectin is rapidly mobilized to the platelet and en-
dothelial cell surface, and serves as a leukocyte adhesion receptor. E-selectin on activated











Leukocyte aggregate and adhesion
Figure 2.4: Leukocyte adhesion on endothelial cells and leukocyte-platelet aggregates for-
mation.
As opposed to platelets, in the absence of leukocyte stimulus, physiological shear stress
alone cannot induce pseudopod formation and 2 integrin expression on leukocytes [58].
However, monocytes have been reported to adhere to the blood vessel wall under non-
uniform shear stress, while no adhesion was observed under laminar shear stress.
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2.3 Blood and Biomaterial Interaction
Hemocompatibility of biomaterials can be evaluated through blood clotting time, thrombin
time, prethrombin time, and responses of platelet [59, 60]. The first event that occurs
when a foreign material comes into contact with blood is the water and plasma protein
adsorption onto its surface. The adsorbed protein layer is essential for the performance of
biomaterials [61,62].
Two plasma proteins, albumin and fibrinogen, have important roles in blood-biomaterial
interactions. Albumin works as an inhibitory protein and inhibits platelet adhesion, while
fibrinogen is an adhesive protein known to enhance the platelet adhesion and activation.
The adsorption of albumin is generally faster than that of fibrinogen because albumin is
much smaller than fibrinogen [61].
Initial reactions of platelets to foreign material, including platelet activation, adhe-
sion and aggregation, are first in the cascade of events eventually leading to stent throm-
bosis [63]. Platelet response is a multiparametric process and is controlled by surface
properties of biomaterials such as morphological characteristics [10], and chemical compo-
sition [61, 64], electrical properties [65], and wettability [66, 67]. Surface treatment tech-
niques, such as mechanical polish, heat treatment, chemical treatment, have been shown to
have a significant effect on the thrombogenicity of materials [68]. Increasing the complex-
ity of the surface microtexture will enhance platelet adhesion and activation [10]. Platelet
adhesion may be more important than platelet aggregation as it occurs before platelet
aggregation. The shape change of platelets on biomaterial surfaces is strongly linked to
the thrombogenicity of materials.
Interaction with stent materials and vascular injury caused by stent placement have
been shown to induce leukocytes activation [55]. Leukocytes have also been found to be
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involved in the early interaction with stent material, interacting and contributing to fibrin
formation [12]. Moreover, it has been found that neutrophil adhesion is dependent on
the wettability of the material surface. For example, hydrophobic materials (glass and
polyethylene) induce a prominent adhesion of neutrophil, while the adhesive surface for
neutrophil is low on hydrophilic material surfaces [12].
2.3.1 Stent metals
Metals possess different degrees of thrombogenicity. Stainless steel has a high electrochem-
ical surface potential, allowing the transfer of electrons to proteins, such as fibrinogen.
This promotes thrombus formation and neointimal hyperplasia. In contrast, titanium has
low electrochemical surface potentials, and is biologically inert [69]. Platelet adhesion
on ST316L and Cobalt-Chromium alloy was observed to be 2-fold higher than that on
Magnesium alloy by SEM analysis [63].
Conventional metals are usually covered with surface oxide films which play an impor-
tant role against protein adsorption and platelet adhesion [61]. A thin film of titanium
oxide is formed shortly after TiAl6V4 contacted with air or blood, so that it is titanium
oxide that blood actually contacts with during incubation. Titanium oxide is widely used
in stent surface modification becaused of its excellent hemocompatibility [59]. Titanium
oxide film composition and thickness of the oxide layer can influence platelet adhesion.
Thicker titanium oxide layers displayed less platelet adhesion than thin oxide layers [70].
Heating, alkali, and H2O2 treated titanium substrate can decrease platelet adhesion and
activation [71]. Compared with titanium alloys, the surface of Cr2O3 is expected to attract
more proteins as the relative permittivity of Cr2O3 is lower than that of TiO2. Taking the
size of albumin and fibrinogen into account, the Cr2O3 surface adsorbs more albumin and
thus has less platelet adhesion [61].
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Nitinol is characterized as a shape memory alloy. Its biocompatibility and corrosion
resistance are comparable or superior to that of ST316L [72]. Fibrinogen adsorption and
platelet adhesion induced by nitinol have been shown in vitro to be significantly lower
than ST316L. Furthermore, nitinol stents tend to exhibit less thrombus formation than
ST316L stent [72].
2.3.2 Coating techniques
There is increasing interest in developing novel coatings to enhance the hemocompatibility
of stent metals. Metal ions can be released from the BMS. For example, one of the concerns
regarding the application of nitinol alloys in the vasculature is that released nickel may
induce a toxic effect on the cells in the system or trigger thrombus formation [68]. Similarly,
all of the elements (chromium, nickel, molybdenum, and manganese) of ST316L could be
detected in the plasma samples after implantation. These metal ions may trigger platelet
activation even at very low concentration [73]. With the use of coating techniques, ion
release may be blocked.
Diamond-like carbon (DLC) coating was developed to enhance the hemocompatibility
of metal implants. A comparative study showed that ST316L promoted a relatively high
degree of platelet adhesion, spreading and aggregation, whereas only modest spreading
and limited aggregation were observed on DLC surfaces. Platelet activation and adhesion
were found to be higher on commercially pure titanium [74], and titanium alloy (TiN and
TiC) [62] than those on DLC coated titanium samples. The index of platelet size on all
of these materials was greater than that for the DLC coating indicating greater platelet
spreading. A lower ratio of adsorbed albumin to fibrinogen is also believed to be responsible
for the greater spreading of platelets observed on these surfaces [62].
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Polymer coating on metal implants is a novel approach to improve hemocompatibility.
Platelet adhesion can be reduced on stainless steel coated with different polymers [75,76].
Compared with unmodified TiAl6V4 samples, platelet deposition on polyphosphorylcholine
(PMPC)-grafted TiAl6V4 and platelet activation in blood were significantly reduced [77].
Adhesion and activation of the platelets on the titanium metal coated with apatite,
albumin-apatite composite or laminin-apatite composite were definitely supressed as com-
pared with those on uncoated titanium metal [11]. Coating of collagen and heparin on
titanium surface improves the biocompatibility of titanium, because collagen is the major
component of extracellular matrix, and heparin is a potent inhibitor of thrombin and factor
Xa in cooperation with antithrombin III [78].
Although various metals and novel techniques have been developed, no real progress has
been made in the development of truly blood compatible materials [79,80]. Most materials
and coatings remain at the laboratory stage. There is still a lack of understanding of
the mechanisms involved in material-induced blood cell activation, especially under flow
conditions. The gap in our knowledge can be illustrated by the fact that all cardiovascular
implants still require anti-platelet and anticoagulant therapies and despite these, there are
still events of thrombotic complications. Hence, there is a need to study the blood-material
interaction and the effect of flow condition in blood cell activation so that better materials




Blood Activation in In V itro Flow
Models
The human body is carefully regulated to prevent unwanted or excessive thrombus forma-
tion so as to avoid occlusion both in the low shear environment in the venous system and
high shear environment in the arterial system. Researchers believe that blood flow plays
a critical role in thrombus formation. Under low shear rate, blood cells move relatively
slowly to the vessel walls and have more opportunity to contact and interact with each
other, because of the adhesion formed between the receptors on the surface of platelets and
their ligands on the endothelium [23, 81]. As shear rate increases, the convective trans-
port of platelets and plasma proteins adhesion to the vessel walls increase correspondingly.
Studies have shown that thrombus formation preferentially occurs in regions where arteries
undergo sharp fluid changes (Figure 3.1), indicating that thrombosis is affected by blood
flow conditions [82].
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Figure 3.1: Blood flow profile within stenosed blood vessel [82].
Blood viscosity varies between individuals, and is dependent on the hematocrit and the
viscosity of plasma. One should expect that blood is a non-Newtonian fluid, because the
volume fraction of erythrocytes is about 40-45% in normal blood. However, blood viscosity
is independent of shear rate under shear rates greater than 100 s−1. Blood is assumed to
have a constant viscosity in large vessels, as vessel diameter is large compared to that of
single cell [83,84]. Therefore, blood is always considered as a Newtonian fluid in the study
of the coronary artery (diameter 3.2 to 4 mm).
Although in vivo studies on coronary artery diseases provide direct information on
how cells react with stent materials in blood circulation systems, their applications are
constrained by high costs and ethical issues. On the other hand, in vitro flow models have
been greatly improved during the last decade. In this chapter, four major types of blood
flow models used in the study of blood cell activation will be introduced. They are the
cone and plate flow system, the chandler loop model, the microfluidic flow model, and the
parallel plate flow chamber.
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3.1 Cone and Platelet Flow System
The cone and plate flow system is a good option for investigating the effects of bulk shear
stress on cellular functions [85,86]. In the cone and plate flow system (Figure 3.2), cells are
either attached onto the stationary plate or suspended in the medium, the cone rotates at
an angular speed !, causing the fluid sample to move in the circumferential direction. At
low shear rates, the flow is approximately uniform and laminar. In contrast, the fluid flow
at high shear rates can begin to make a transition to three dimensional flow because of the
centrifugal forces in the radial direction [43]. However, since the angle  between the cone
and plate is small, the radial flow is small because the viscose and surface tension forces
are much larger than the centrifugal forces, and can be neglected in thrombosis research.





In biological experiments, shear rate produced in the cone and plate flow system ranges
from 0 to 10,000 s−1. Cone angle varies from 0.3 to 2 degrees. The shear rate is less than
2500 s−1 for neutrophil and endothelial cell studies, and it can reach 5000 s−1 in studies
of shear-induced platelets activation [87,88].
While the cone and plate flow system enables the study of the effect of various shear
rates on cells within one experiment, hemolysis has been reported on several occasion [87,
88]. Thus, red blood cells or whole blood cannot be tested. Unfortunately, this significantly















Figure 3.2: (a) Commercial product whose cone is made of titanium and plate is made
of stainless steel (BS: 3900 A7, Research Equipment, UK), (b) The schematic of a typical
cone-and-plate flow system.
3.2 Chandler Loop model
The chandler loop system was first created to form thrombi outside the human body
in 1958. The system usually comprises a 50 cm long tube, with inner diameter of 4 to 6
mm [89,90]. The circular tubes are connected end-to-end after loading experiment samples
(Figure 3.3(a)). The loop is then mounted on a rotating wheel. The chandler loop system
is adapted to use in an incubator or water bath (Figure 3.3(b)). The rotation speed can
be set at 20 to 60 rpm. The system is commonly used to mimic the blood flow condition
in large vessels. However, one disadvantage of the sytem is the large volume of blood
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consumption. Based on the tube mentioned above, 5 to 10 ml blood is needed per test
sample. Hence, this design is not practical for either experiments with many test samples
or experiments using blood from small animals. Moreover, it can only produce shear rates
under 500 s−1, and lacks the ability to produce high shear rates. The shear rate in the
healthy human coronary artery is above 440 s−1 [23], and pathological shear rate is even
much higher. Therefore, the chandler loop system is not a good candidate for studying the
effect of pathological shear rate on blood cell activation.
(a) (b)
Figure 3.3: Chandler loop models. (a) Tube and connector, (b) Chandler loop system used
in water bath (picture source: Chandler-Loop-System, Germany)
3.3 Novel Microfluidic Devices
Blood consumption is a major issue in blood experiments, and is limited by donors and
the volume in each blood collection. As a result, various microfluidic flow systems have
been developed, which can reduce the amount of blood volume for a single test sam-
ple [44,91,92]. Figure 3.4(b) is a typical example of microfluidic device. Photolithography
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is first employed to fabricate the flow channels. It can minimize the channel width to a few
hundred micrometers or even lower. This makes the cross sectional area very small, leaving
the surface areas relatively large. This micro-dimension concept is especially practical for
the cell adhesion experiment. Another beneficial component of such a system is the pro-
grammable pump, producing controllable flow rates. Multiple channels on the same device
also make it possible to operate parallel experiments simultaneously under different shear
conditions. Thus, shear force, flow rate, and temperature can be independently controlled
in all wells allowing to potentially perform 24 experiments at once. Most devices are also
made of silicone rubber polydimethylsiloxane (PDMS), an inexpensive but most impor-
tantly biocompatible and transparent. The material is inexpensive, and most importantly
biocompatible and transparent. Thus, a microscope or a camera can also be added to the
system to provide direct observation on cell adhesion and rolling.
Figure 3.4: BioFluxTM microfluidic well-platelet. The system is coupled to an SBS-
standard 48-well plate. Each fluidic channel has a unique input and an output well. Up to
24 independent experiments can be run on a single BioFlux plate.
Despite the advantages mentioned above, microfluidic design also has some limitations.
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Due to its micro-dimensions, it can mimic the flow conditions in capillary blood vessels
with a wide range of shear rates. However, it is not able to mimic the flow conditions
in larger blood vessels, such as coronary arteries. Geometry differences between large
blood vessels and capillaries result in different shear conditions, because blood viscosity
decreases as the blood vessel diameter is reduced [93]. This phenomenon is named as
Fahraeus-Lindqvist effect. Furthermore, blood in a micro-sized vessel is not a Newtonian
fluid any more, because red blood cells move over the center of the vessel, leaving plasma
flows near the vessel wall. This may result in shear rate calculation and measurement much
more complex. Thus, it is not a suitable device for stent related thrombosis study.
3.4 Flow Chambers
Flow chamber is another popular experimental device that has been widely used in blood-
material interaction study. It was originally proposed by Lawrence et al. in 1958. After
many years of development, various designs have been derived, such as parallel-plate flow
chamber, rectangular flow chamber, and vertical step flow chamber. Figure 3.5 illustrates
the design of these chambers. These flow chambers can produce not only constant shear
rates [43], but also pulsatile flow and turbulent flow [94,95]. Moreover, flow chambers can
generate a wide range of shear rates, from 1 up to 104 s−1 with limited volume of blood as
a syringe pump or roller pump can be used. It is also convenient to mount material wires
or strips into the chamber, or coat the gasket with cells of interest [94]. Cell adhesion and
movement in the chamber can be monitored or recorded by microscope or camera.
Taking blood vessel geometry, blood volume, and shear condition into account, the
parallel-plate flow chamber appears to be the optimum device to study stent material-
induced blood cell activation. The diameter of the tubing in the flow chamber system is
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about 1.52 mm, which is close to the diameter of coronary arteries. Second, the blood
volume needed for each sample can be reduced to less than 1.5 ml, so that more tests can
be done with 5-10 ml of blood. For example, with 5 ml blood, which is acceptable for most
blood donors, at least 3 tests can be operated at the same time. Third, a parallel-plate flow
chamber can produce both physiological and pathological shear rates of coronary arteries,










Figure 3.5: Types of flow chamber designs. (a) Parallel-plate flow chamber, (b) Rectangular





4.1.1 Reagents and monoclonal antibodies
LPS (Escℎericℎiacoli serotype 0111:B4), endotoxin-free water, ethylenediaminetetraacetic
acid (EDTA), thrombin receptor-activating peptide SFLLRN, 50% glutaraldehyde solution,
and paraformaldehyde were purchased from Sigma-Aldrich Co(Oakville, ON, Canada).
Phosphate-buffered saline (PBS) from Fisher Scientific Inc(Ottawa, ON, Canada) was used.
To quantify platelet activation, aggregates, and platelet microparticle formation, flu-
orescein isothiocyanate (FITC) conjugated mouse monoclonal antibody against human
glycoprotein IIb/IIIa (CD61) (Cat: 555753) was used. R-phycoerythrin-cytochrome 5
(PE-Cy5) conjugated monoclonal antibody against CD45 (Cat: 555484) the pan leuko-
cyte common antigen was used to label leukocytes. Leukocyte activation and tissue factor
expression were detected through FITC conjugated mouse monoclonal antibody against
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Mac-1 (CD11b) (Cat: 557701) and R-phycoerythrin (PE) monoclonal antibody against
TF (Cat: 550312) respectively. All the monoclonal antibodies were purchased from Bec-
ton Dickinson Pharmingen (San Diego, CA, USA). FACS lysing solution, a red blood cell
lysing buffer also containing paraformaldehyde, was obtained from Becton Dickinson (San
Jose, CA). All other chemicals were of analytical reagent grade.
4.1.2 Metal samples and preparation
ST316L disks (thickness 0.5 mm, diameter 12mm) and TiAl6V4 disks (thickness 0.52 mm,
diameter 12mm) were obtained from Goodfellow Co. (Oakdale, PA, USA). TiAl6V4 wire
was purchased from Fort Wayne Metals (Fort Wayne, IN, USA), while ST316L wire was a
generous gift from this company. To remove endotoxin on the surfaces and sterilize mate-
rials, both metal disks and wires were first cleaned twice in 70% ethanol and then rinsed
in phosphate buffer (PBS). All washes took place in an ultrasonic water bath each time
for 30 min. Rinsing samples in endotoxin-free water was performed after each ultrasonic
clean cycle. Sterilized metals were then immersed in PBS and stored at 4 ℃ for 2 weeks
maximum.
4.1.3 Blood collection
This study was approved by the research ethics committee of the University of Waterloo.
Blood samples were taken by venipuncture with a 21 gauge needle from healthy donors
(average age 30 years) who were medication-free for at least 3 days. Blood was then
transferred to a polypropylene tube preloaded with 5U/ml anti-coagulant heparin (Sigma
Aldrich Co), and inverted 2 to 3 times. Heparinized blood was kept at room temperature




To assess the effect of material on blood cell activation, static experiments were first per-
formed by incubating material samples with heparinized whole blood or platelet rich plasma
(PRP). PRP was prepared by centrifugation at 1000 g for 10 min at room temperature.
PRP supernatant was then carefully collected and transferred into a small vial.
Sterilized ST316L and TiAl6V4 disks were fixed separately in one of the wells of a
24-well plate with a small TygonTM tubing ring (12.7 mm inner diameter, 15.9 mm outer
diameter, and 10mm height; VWR, Mississauga, ON, Canada). The silicone tubing rings
had also been cleaned in an ultrasonic cleaner as previously described above. A disk of
sterilized silicone sheet (medical grade, thickness 0.015 inch; Specialty Manufacturing Inc,
Saginaw, MI, USA) was placed at the bottom of a well and used as negative control,
because of the good biocompatibility of silicone. Also, an empty polystyrene well was used
as a positive control. TygonTM silicone tubing rings were also used in the control wells to
ensure that blood was exposed to the same surface area with all samples. Samples were
incubated with 300 l heparinized whole blood or PRP at 37 ℃ for 2 hours. To prevent
blood from settling, the 24-well plate was placed on an orbital plate shaker (Model type:
Standard 3500, VWR) rotating at 300 rpm.
4.2.2 Flow experiment
The parallel-plate flow chamber was adopted because of the advantages mentioned previ-
ously in Chapter 3.4. Flow chamber kits were purchased from Glycotech (Gaithersburg,
MD, USA). The flow chamber was comprised of a flow deck, a silicone gasket and a glass
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side. The thickness of the gaskets was chosen to accommodate the laboratory metal wires
that had a diameter of 0.005 inch. A smaller gasket chamber width was also preferred to
reduce the blood volume needed for a single sample. Thus, the gasket with a thickness of
0.01 inch, a width of 2.5 mm and a chamber length of 19mm was selected.
For a healthy human, while also varying with age, gender, and lifestyles, the shear rate
in coronary artery can be considered to be approximately 500 s−1. For patients with CAD
treated by stent placement, shear rate in their coronary arteries may also be considered
to be close to the normal value in the short term, due to the stent support against blood
vessel wall. Thus, 500 s−1 shear rate was chosen as the principal rate to be used in in
vitro flow experiments. Meanwhile, shear rates of 100 s−1 and 1500 s−1 were also selected
to study the effects of different flow conditions on blood cell activation.
A pump was needed to produce blood flow and mimic the flow condition in blood vessels.





where  is the shear rate, Q is the flow rate, w is the flow chamber width and ℎ is the
chamber height. Based on the chamber gasket parameters described above, flow rates of
about 160, 800, and 2400 l per minute were required to produce shear rates of 100, 500,
and 1500 s−1, respectively.
Peristaltic pump
A peristaltic pump (MasterFlex 77120-32, Cole Parmer, Montreal, QC, Canada) was used
to circulate blood samples. SilasticTM laboratory tubing (Dow Corning, Midland, MI,
USA) was used to connect the whole system, as shown in the schematic diagram in Fig-
ure 4.1(a). SilasticTM tube was secured in the retainers and occlusion bed (Figure 4.1(b)).
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Blood sample in a 5 ml polypropylene tube first went through the peristaltic pump, and
then entered into the circular flow chamber, and finally returned to the polypropylene
tube. Continous flow could be produced by repeating this cycle. Since the pump could
not display the actual output flow rate, the appropriate setting for the selected flow rate
was first determined by measuring the time blood took to go through a 20 cm long silastic







S is the inner cross-sectional area of the tube
Q is the flow rate
Q
(c)
Figure 4.1: Peristaltic pump circulation models. (a) Schematic picture of blood circulation
driven by peristaltic pump, (b) Peristaltic pump front view shows the tubing installation,
(c) Flow rate was determined and then adjusted according to the time blood took to flow
through a 200 mm long tube.
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Syringe pump
A Cole-Parmer 75900-50 programmable 6-channel syringe pump was purchased to perform
multiple sample tests simultaneously. Silastic tubing was used to connect the syringe, flow
chamber, and blood sample tube (see Figure 4.2(a)). Blood was slowly withdrawn into
the system. After the flow chamber and tubing were filled up with blood, the syringe was
disconnected to expel the air bubbles and reconnected, and then loaded onto the syringe
pump. To minimize further introduction of air bubble, standard BD 5 ml syringes were
adopted.
According to the chamber width and length, 4 pieces of metal wires with a total length
of 70 mm could be fixed into the chamber with minimum influence on the flow conditions.
Figure 4.2(b) provides a bottom view of flow chamber preloaded with TiAl6V4 wires. A
flow chamber configured without metal wire was used as negative control to obtain the
baseline of shear effect. The glass slide surface was entirely covered by sterilized silicone
sheet to minimize blood cell activation.
The total length of the tubing connecting the flow system was 340 mm, with a system
dead volume of about 800 l. This length was convenient for the experimental operation in
the 37 ℃ incubator. A full circulation cycle was defined as blood sample being withdrawn
into the syringe, then pumped back into the sample tube. Extra blood was needed to
increase the circulation period. Taking the blood consumption and the times of blood flow
direction change into account, a period of about 2 min was selected. Based on the above




















Figure 4.2: Blood circulation in syringe pump flow system. (a) Blood circulation in flow
chambers was driven by the syringe pump, and the blood flow direction alternated once
every cycle, (b) 70 mm metal wire was cut into 4 pieces to fit into the chamber (bottom
view of the flow chamber and section view A-A).
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Experimental controls
For all experiments, at the beginning of each experiment, a small aliquot of blood sam-
ple, -Rest0, was collected and directly processed for flow cytometry. Another 200 l of
heparinized whole blood, -Rest2h, was set aside in a microcentrifuge tube and incubated
for 2 hours at 37 ℃ without flow or agitation. Blood samples added with LPS (5g/ml)
and EDTA (8mM final concentration) were also used as positive and negative control,
respectively for the leukocyte study. Finally, as a positive control for platelet activation,
thrombin peptide SFLLRN was added at the end of the 2-hour incubation to a small aliquot
of Rest2h.
Platelet stimulation
To verify the performance of the in vitro flow model and assess how platelet activation,
especially platelet microparticle formation, changed over time under flow condition, experi-
ments with activated platelets were performed. Platelets were first pre-activated by adding
200 l thrombin peptide SFLLRN into 3.5ml whole blood. After incubation at 37 ℃ for 30
min, flow-wholeblood sample was then circulated in flow chamber. The SFLLRN-activated
blood was divided into 3 samples: (1) 1.7 ml of activated blood was directly circulated in
flow chamber, flow-SF; (2) EDTA (85 l, 8mM final concentration) was added to 1.7 ml
of activated blood, and then circulated in flow chamber, flow-SF+EDTA; (3) 100 l of
activated blood was left ”sitting” for 2 hours at 37 ℃, SF-rest. At the beginning of flow
experiment, 200 l of normal whole blood in a polypropylene tube was used as control
Rest2h. Another 1.7 ml normal whole blood was also circulated in the flow chamber, flow-
wholeblood. Small aliquots of blood were collected at 15 min, 60 min, 90 min, and 120
min to analyze the changes in platelet activation over time. To measure platelet activation
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under pathological shear conditions, 3 ml blood sample or PRP were circulated at shear
rate of 6200 s−1 for up to 45 min.
4.2.3 Flow cytometry
Flow cytometer
Flow cytometry is able to count and measure the properties of microscopic particles. After
staining with fluorescent antibodies, samples are injected into a flow cytometer and enclosed
by an outer sheath that contains faster flowing fluid, as shown in Figure 4.3. The sheath
creates a single file of cells or microparticles which then passes through one or more laser
beams. Light scattering or fluorescence emission provides information about the particle
properties. Various dyes with difference absorbance and emission wavelength can be used
to label cells, such as FITC, PE, Percp, and Alexa FluorTM series. The optical signal on
cells is then selectively filtered by different lens and detected by separate fluorescence (FL)
channels.
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Figure 4.3: Schematic overview of a typical flow cytometer setup (figure source: Abdserotec
Co.).
Fluorescent antibody labeling
In the present experiments, flow cytometry samples were processed before and after blood
incubation with stent materials. Small aliquots of blood (5 and 30 l) were diluted in 50 l
HEPES-Tyrode’s buffer (HTB: 137mM NaCl, 2.7mM KCl, 5mM MgCl2, 3.5mM HEPES,
1g/L Glucose, and 2g/L BSA, PH 7.4) containing saturating concentrations of monoclonal
antibodies. Specifically, 8 l anti-CD61 antibody was added to each platelet sample. For
leukocyte study, 7 l anti-CD45 antibody was added to all leukocyte samples. Leukocyte
samples were divided into three groups: (1) group CD11b to study leukocyte activation, (2)
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group CD61 to study leukocyte-platelet aggregates, and (3) group TF to study monocyte
tissue factor expression. 5 l anti-CD11b antibody was added to samples in group CD11b,
8 l antibody anti-CD61 was added to samples in group CD61, 6 l anti-TF antibody was
added to samples in group TF respectively. All samples were incubated for 30 min at 4℃.
After incubation, samples for platelet study were diluted with 200 l HTB and fixed
with 200 l 2% paraformaldehyde (final concentration 1%). For leukocyte samples, red
blood cells were lysed with 700 l FACS lysing solution, as they could hinder the detection
of the target population. All leukocyte samples were incubated in the dark for 10 min.
After that, leukocyte samples were washed at 1200 rpm for 6 min, and diluted with 150 l
HTB and fixed with 150 l 2% paraformaldehyde.
Blood cell identification
In the present study, prepared blood samples were read on a three-color FACSCalibur
flow cytometer (Becton Dickinson). Data acquisition and analysis were performed using
CELL-Quest software (Becton Dickinson). Blood cells were normally detected by their
forward scatter (FSC) and side scatter (SSC) profiles, corresponding to cell size and cell
complexity (Figure 4.4). In the absence of a monoclonal antibody against a specific antigen,
neither platelets nor leukocytes could be reliably identified in whole blood with FSC vs
SSC characteristics.
Upon the addition of FITC labeled anti-CD61 antibody, platelets were identified by
CD61-positive events in fluorescent channel-1 (FL-1). Platelet microparticles (PMPs) were
defined as events being CD61 positive but smaller than intact platelets, based on forward
light scatter, and were reported as a percentage of total platelet events. A FSC median
value of platelets was first obtained from the initial blood sample Rest0, the median value is
directly proportional to the average size of platelets in blood sample. The FSC upper limit
41
of PMPs was set to 35% of the median value of platelets, because PMPs are less than 1 m
and platelets are around 2-3 m. Fluorescence intensities of CD61 and P-selectin on both
platelets and platelets + PMPs were also recorded as a measure of platelet activation. The
results are later reported either directly in arbitrary fluorescent units or as a percentage






























Figure 4.4: Flow cytometric analysis of platelets. Platelets and PMPs were analyzed by
FSC vs SSC dot plot. Both FSC and SSC were set to logarithmic mode. Platelets were
identified in Gate 2. Left quadrant represents the percentile of PMPs.
As shown in Figure 4.5(a), leukocyte subpopulations were clearly identified by a dot plot
of FSC vs SSC after red blood cells lysis. Neutrophils and monocytes were gated for further
analysis. The activation of leukocytes was quantified by measuring CD11b expression.
Formation of leukocyte-platelet aggregates was determined using the fluorescent intensities
of CD61 on leukocytes as illustrated in Figure 4.5(c). Tissue factor expression on monocytes
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Figure 4.5: Flow cytometry analysis of leukocytes. (a) Leukocytes can be distinguished
according to their FSC vs SSC characteristics; gate 1 identifies PMNs while gate 2 is
for monocytes. (b) Leukocytes can also be identified in a dot plot of SSC versus PE-
Cy5 conjugated anti-CD45 antibody (FL-3 channel); gate 3 identifies PMNs while gate 4
monocytes. (c) Channel FL-1 fluorescent histogram where FITC conjugated anti-CD11b
and anti-CD61 antibodies can be observed. (d) Dot plot of monocyte population against
fluorescent signal of PE-conjugated anti-TF antibody (channel FL-2).
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and anti-CD45 positivity (Gate 2 and Gate 4). Both the fluorescent intensity and the
percentage of monocytes staining positive for TF expression were recorded (Figure 4.5(d)).
The leukocyte results are later reported as a percentage expression (up or down regulation)
relative to one of the experimental controls.
4.2.4 Scanning Electron Microscopy analysis
For electron microscopy of adherent blood cells, ST316L and TiAl6V4 metal samples, and
a piece of silicone sheet in flow chamber were rinsed with 0.2mM sodium phosphate buffer
(v/v 36 ml Na2HPO4: 14 ml NaH2PO4 PH 7.2) after blood-material incubation, fixed
with 2.5% glutaraldehyde and stored at 4 ℃ for a maximum of 30 days. The day before
microscopic analysis, samples were dehydrated with a graded series of ethanol dilutions
(25% to 100%) and dried overnight. The metal samples were coated with 8-10 nm thick
gold by sputtering, and observed with a scanning electron microscope (LEO FESEM 1530)
for cell adhesion and aggregation analysis.
4.2.5 Statistical analysis
All results are reported as the mean ± standard deviation (SD). To evaluate the effects
of stent metals on platelet and leukocyte activation under the same blood flow condition,
one-way ANOVA followed by Tukey HSD test was carried out using SAS 9.2 (Cary, NC,
USA). A p value of less than 0.05 was required for statistical significance. The number of
experiments was always equal to or greater than three.
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Table 4.1: Flow cytometry experiment summary
Static
condition
Heparinized whole blood was incubated with TiAl6V4 and ST316L disks,
silicone sheet, and polystyrene for 2 hrs at 37 ℃.
Platelt study: negative control-Rest0, positive control-SFLLRN.
Leukocyte study: negative control-EDTA and Rest2h, positive control-
LPS.
Platelet rich plasma (PRP) was incubated with TiAl6V4 and ST316L




Peristaltic pump: heparinized whole blood was circulated at 500 s−1 in
flow chamber loaded with ST316L wires and no wires.
Negative control: Rest2h
Syringe pump:
1. Heparinized whole blood was circulated at 100 s−1, 500 s−1, and 1500
s−1 for 2 hrs at 37 ℃ in flow chambers loaded with TiAl6V4 wire, ST316L
wire, and without wire. Platelt study: negative control-Rest0, positive
control-SFLLRN. Leukocyte study: negative control-EDTA and Rest2h,
positive control-LPS
2. Heparinized whole blood and PRP were circulated at 6200 s−1 for
30-45 min at 37 ℃. Flow cytometry results before and after circulation
were compared.
3. Flow-sf, Flow-sf+edta, and Flow-wholeblood were circulated at 500




In this section, flow cytometry data from blood samples incubated under static and three
different shear conditions are presented. The effects of material and shear stress on platelet
and leukocyte activation, leukocyte-platelet aggregation, and tissue factor expression are
compared. SEM images of cell adhesion and aggregation, and fibrin deposition on the
surface of materials are presented.
5.1 Blood Cell Activation Under Static Condition
5.1.1 Platelet activation in platelet rich plasma
After TiAl6V4 and ST316L metal disks were incubated with 300 l platelet rich plasma
(PRP) at 37 ℃ for two hours, platelet activation was measured by flow cytometry with
the PRP Rest2h being used as a negative control. Table 5.1 presents the data in terms
of platelet microparticle (PMP) formation and platelet activation using the expression of
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CD61 on intact platelets and all CD61 positive events (platelets and platelet microparti-
cles). No significant difference in platelet microparticle formation in PRP was found be-
tween the Rest2h and metal samples. However, with PRP having contacted TiAl6V4, the
CD61 signal intensity for all platelet events was significantly lower than ST316L (p=0.036)
and Rest2h (p=0.025) samples.
Table 5.1: Platelet activation after metal disks incubated with PRP (n=3)
Marker % PMPs Platelet % CD61 Total % CD61
PRP TiAl6V4 8.8±2.8 93.8±7.7 92.7±3.9 ∗
PRP ST316L 8.9±4.5 101.8±8.6 100.7±2.6
PRP Rest2h 7.8±3.2 100±0 100±0
% PMPs represents the percentage of platelet microparticle formation in blood, as
identified by sidescatter characteristics and CD61 positive events.
% CD61 signal expressed as a relative percent to the PRP Rest2h.
∗ TiAl6V4 significantly different from ST316L and Rest2h (p<0.04).
5.1.2 Platelet activation in whole blood
As expected, platelets were significantly activated with SFLLRN (positive control) with a
platelet microparticle formation of about 60%, confirming that platelets functioned prop-
erly and thus would be able to respond adequately to a platelet stimulus. As can be seen
in Table 5.2, no difference in platelet activation was found between the negative control
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(Rest0) and all biomaterials that were incubated with blood for 2 hrs under static condi-
tions. Compared with other biomaterials, TiAl6V4 had the lowest CD61 signal intensity,
albeit not statistically significant.
Table 5.2: Platelet activation after incubation in blood under static conditions (n=3)
Marker % PMPs Platelet % CD61 Total % CD61
Rest0 6.9±2.1 100±0 100±0
SFLLRN 59.7±10.8† 94.5±5.8 60.9±4.4†
TiAl6V4 4.8±2.1 80.6±3.0∗1 82.2±1.9∗2
ST316L 5.0±2.4 94.6±7.0 96.3±5.8
Silicone 5.5±2.8 98.5±10.2 100.0±9.2
Polystyrene 6.1±3.8 97.6±0.7 98.6±2.2
% PMPs represents the percentage of platelet microparticle formation in blood, as
identified by sidescatter characteristics and CD61 positive events.
% CD61 signal is expressed as a relative percent to the negative control Rest0.
∗1 TiAl6V4 was significantly lower than Rest0, Silicone, and Polystyrene (p<0.05).
∗2 TiAl6V4 sample was significantly lower than other samples (p<0.05).
† SFLLRN was significantly different from other samples (p<0.002).
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5.1.3 Leukocyte activation in whole blood
Neutrophils and monocytes were identified using the anti-CD45 antibody. Antibodies
against CD11b, CD61, and TF were employed to study leukocyte activation, leukocyte-
platelet aggregation, and TF expression on monocytes. Leukocytes activation in negative
control EDTA and positive control LPS are also reported to ensure the validity of experi-
mental data and demonstrate the ability of blood leukocytes to be activated under normal
conditions. Leukocyte activation induced by materials under static condition is reported
in Table 5.3.
As expected, the neutrophil CD11b up-regulation in EDTA and Rest2h samples was
low. Contact with metallic materials led to a higher expression of CD11b on neutrophils,
and was in the order of Silicone≈ST316L<TiAl6V4≈Polystyrene although no statistically
significant differences were observed with the Rest2h. With CD11b up-regulation on mono-
cytes, high variations in expression were obtained between experiments making any com-
parison between sample conditions difficult.
With exposure to biomaterial under static conditions, formation of leukocyte-platelet
aggregates appeared to be similar for all materials. Higher CD61 intensities were usually
observed on monocytes, suggesting that an increased number of platelets bound to mono-
cytes compared to neutrophils. Surprisingly, compared to all other conditions, leukocyte-
platelet aggregates in the two-hour resting blood sample (Rest2h) was significantly higher.
Minimal tissue factor expression on monocytes (both the expression and the population

















































































































































































































































































































































































































































































































































5.2 Blood Cell Lysis in The Peristaltic Pump System
A blood flow experiment was first performed using the peristaltic pump. After circulating
at a shear rate of 500 s−1 for two hours, 1 ml blood was collected from each sample and
transferred into a small vial. After centrifuging at 1000 g for 10 min, reddish plasma
was observed for both blood samples with and without metal wires (Figure 5.1(a)). The
normal color of plasma being yellow (Figure 5.1(b)), it was obvious that red blood cell lysis
had occurred during the recirculation with the peristaltic pump. The fact that lysis was
observed in both samples, suggested that it was not the metal wires that were responsible
for the lysing but the in vitro flow system. It is also likely that other types of blood cells









Figure 5.1: Blood lysing with peristaltic pump. (a) Reddish plasma after circulation with
and without metal wires, (b) Normal color of platelet rich plasma.
Table 5.4 reports the platelet and leukocyte activation after two-hour incubation. Com-
pared with the control Rest2h, the lower CD61 values observed for both flow samples
suggest potential platelet damage. On the other hand, both CD11b up-regulation and
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leukocyte-platelet aggregates were higher in flow samples, but in the context of the red
blood cell lysis observed under flow conditions, it is difficult to interpret these results as
true material-induced activation. None of the blood samples had significant monocyte TF
expression.
Table 5.4: Platelet and leukocyte activation after recirculation (n=1)
% PMPs Platelet neutros monos MPA monos % monos
Marker CD61 CD11b CD11b CD61 TF express TF
ST316L 27.2 150 453 403 1192 8.4 0.7
No wire 12.6 192 254 308 784 7.9 0.5
Rest2h 19 210 145 128 583 9.1 1.8
% PMPs represents the percentage of platelet microparticle formation in blood, as
identified by sidescatter characteristics and CD61 positive events.
CD61, CD11b, MPA, and TF are presented as the signal in arbitrary fluorescent units of
gated platelets, leukoyctes, monocyte-platelet aggregates, and monocytes.
% monos express TF shows the percent of TF positive monocytes.
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5.3 Blood Cell Activation Under Shear Conditions
5.3.1 Platelet activation
Platelet activation under normal shear rates
As shown in Table. 5.5, the formation of platelet microparticles in blood was neither
affected by material nor shear conditions. Expression of CD61 on platelets was comparable
between materials and shear conditions, except for TiAl6V4 at 1500 s−1 where an increase





















































































































































































































































































































































































































































































































































SFLLRN induced platelet activation at 500 s−1
As increasing shear rate from 100 s−1 to 1500 s−1 did not appear to induce significant
platelet microparticle formation, to ensure that platelet microparticles were not disappear-
ing over time in the in vitro flow model, activated blood sample containing a significant
population of platelet microparticles was circulated in the flow system for 2 hours at 500
s−1. Blood was first activated by SFLLRN (as described earlier in the previous section)
and the level of platelet microparticles was then monitored over 2 hours in the flow system.
After activation with SFLLRN, the initial platelet microparticle level in activated blood
was 30±7%, and 6±0.9% PMPs were present in non-activated blood. As can be seen
in Figure 5.2, an increase in microparticle formation was initially observed in SFLLRN
activated blood samples under flow conditions. However, with increasing recirculation
time, platelet microparticle presence in activated blood then decreased. Over the 2 hour
recirculation at 500 s−1, a small but steady increase in platelet microparticle formation
was observed in normal blood. At 2 hours, 12±6% microparticles were present in normal































Figure 5.2: Platelet microparticles in blood exposed to 0 and 500 s−1 over 2 hours (n=3).
All SF samples were from the same initial blood sample that had been activated with
SFLLRN to generate platelet microparticles. EDTA was added to activated blood to
prevent binding of platelets to leukocytes. Flow-sf: activated blood sample circulated
at 500 s−1; Flow-sf+edta: activated blood sample was inhibited with EDTA and then
circulated at 500 s−1; Flow-wholeblood: normal blood sample circulated at 500 s−1; SF-
rest: sitting activated blood sample; Rest2h: sitting normal blood sample.
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Platelet activation under pathological shear condition
To further test the ability of the in vitro flow model to generate platelet microparticles,
platelets were tested under higher shear conditions. Three milliliters of blood (n=2) and
platelet rich plasma (PRP) (n=1) was circulated at 6200 s−1 for up to 45 min, and signif-
icant platelet activation was observed. Table 5.6 shows that PMP percent almost doubled
in both whole blood and PRP sample after circulation. Correspondingly, the average size of
platelets decreased, leading to the decrease of the total CD61 signal. CD61 fluorescent in-
tensity of gated platelets in blood A and PRP sample decreased, while it slightly increased
in blood B. Different circulation time (Blood A 30 min; Blood B: 45 min); the platelet
activation status before circulation may have lead to the difference. Reddish plasma was





Figure 5.3: Blood cell lysis (left tube) after 30 min circulation at 6200 s−1.
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Table 5.6: Platelet activation at 6200 s−1
Shear % PMP Platelet CD61 Total CD61
Blood A before 15.0 228 189
after 26.7 154 112
Blood B before 11.2 113 103
after 27.4 117 97
PRP before 5.4 202 188
after 13.1 151 128
% PMPs represents the percentage of platelet microparticle formation in blood, as
identified by sidescatter characteristics and CD61 positive events.
CD61 represents the absolute value of fluorescent intensity.
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5.3.2 Leukocyte activation
Leukocyte activation as expressed by CD11b up-regulation is presented in Figure 5.4.
Generally, leukocyte activation in positive control LPS was significantly higher than all
other samples. As shear rate increased, the leukocyte activation in TiAl6V4 and ST316L
samples decreased. The result shows that TiAl6V4 induced less leukocyte activation than
ST316L under three shear conditions, whereas their difference at a specific shear rate was
not significant. Neutrophil activation in ST316L was significantly higher than EDTA and
Rest2h sample under all three shear rates. When shear rate increased from 100 s−1 to
1500 s−1, neutrophil activation induced by TiAl6V4 (P=0.0102) and ST316L (p<0.05)
wire decreased significantly. Shear effect on monocyte activation in both TiAl6V4 and
























































Figure 5.4: (a) Neutrophil and (b) monocyte activation under three shear rates. The values
are expressed as a percent of CD11b fluorescent signal relative to positive control LPS.
Leukocyte activation in LPS, EDTA, and Rest2h were consistent between experiments.
The extent of activation in EDTA and Rest2h was similar, and was 17±6.7% for neutrophil
activation and 34±13.9% for monocyte activation. ∗ Significantly higher than EDTA and
Rest2h. † Significantly lower than TiAl6V4 at 100 s−1 and 500 s−1. ‡ Significantly lower
than ST316L at 100 s−1. (n=3 to 5, mean±SD).
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Under flow conditions, more leukocyte-platelet aggregates were formed in TiAl6V4
samples rather than in ST316L samples, except for the result in the 1500 s−1 group. The
leukocyte-platelet aggregates in TiAl6V4 at 100 s−1 were significantly higher than those at
500 s−1 and 1500 s−1. However, the Rest2h control at 500 s−1 was higher than the other
two shear conditions, which might lead to relatively lower leukocyte-platelet aggregates.
Monocyte TF expression in TiAl6V4 sample was lower than in ST316L as can be
seen from the fluorescent intensity of anti-TF antibody (Figure 5.6(a)). As shear rate
increased, the monocyte tissue factor expression decreased, albeit not significantly. The
maximal percent of TF positive events was obtained at 500 s−1, but the variability between
donor responses was high. The percent of TF positive cells in TiAl6V4 at 1500 s−1 was




















































Figure 5.5: (a) Neutrophil-platelet aggregates, and (b) monocyte-platelet aggregates for-
mation under three shear conditions. Fluorescent intensity of samples is expressed as a
































































Figure 5.6: (a) TF expression on monocyte is expressed as a percent of fluorescent signal
relative to LPS. Same extent of monocyte TF expression (42±5.8%) was obtained in EDTA
and Rest2h. (b) Percent of monocytes staining positive for TF. * Significantly lower than
other groups. (n=3 to 5, mean±SD).
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5.4 Morphological Analysis of SEM Images
5.4.1 Bare metal disks
In order to explore the role of biomaterial-mediated cell adhesion and activation, SEM
images of bare TiAl6V4 and ST316L disks were first obtained. Both disks were washed
following the protocol described in Section 4.1.2. As can be seen from Figure 5.7, a ”basin”
was located at the top right corner, and smooth ”islands” were separated by cracks on the
ST316L disk surface. The TiAl6V4 disk featured some protrusive irregular shaped ”grains”
on its surface.
(a) (b)
Figure 5.7: SEM images of bare metal disk. (a) cracked ST316L surface, and (b) protrusive
TiAl6V4 surfaces.
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5.4.2 Metal disks incubated with blood under static condition
Red blood cell adhesion and aggregates, and large flake-like fibrin were frequently seen
on the surface of ST316L disk as shown in Figure 5.8(a). The thickness of fibrin was
more than 2-3 times the diameter of red blood cells. It appears that fibrin deposition may
promote red blood cell adhesion and aggregation as red blood cell aggregates were often
surrounded by fibrin, as shown in the magnified image in Figure 5.8(a). Platelets (and
possibly some microparticles) were also attached to the fibrin. Figure 5.8(b) shows that
highly activated platelets generated tethers and formed net-like platelet aggregates along
fibrin. Some activated leukocytes were also observed on the metal surface (Figure 5.8(c)).
Short fibrin tethers but not large flake-like fibrin were always observed on the surface
of TiAl6V4 disk (Figure 5.8(d)). Activated platelets with clear pseudopods, and small
aggregates were presented in Figure 5.8(e). Red blood cells and their aggregates were also
found on TiAl6V4 surface (Figure 5.8(f)). Comparing the two metal surfaces, there were






Figure 5.8: Blood cell adhesion and aggregation on metal disks under static condition. (a)
to (c) display fibrin clot and cell adhesion on ST316L disk (magnification 646X, 8.33kX, and
10kX), while (d) to (f) illustrate TiAl6V4 disk surface after static incubation (magnification
450X, 7.51kX, and 4.65kX).
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5.4.3 Metal disks incubated with platelet rich plasma
Fibrin tethers and large number of platelets and platelet aggregates were adhered on the
surface of ST316L disk, as shown in the Figure 5.9(a). Two morphological forms of ac-
tivated platelets can be identified: dendritic and spread dendritic, indicating different
activation stages. Some small particles, most likely PMPs, were also present on the sur-
face. Figure 5.9(b) shows only a few platelets were on TiAL6V4 surfaces. However, these













Figure 5.9: (a) ST316L disk and (b) TiAl6V4 disk incubated with platelet rich plasma.
5.4.4 Metal wires under flow conditions
Under shear rate of 100 s−1
At 100 s−1, small pieces of fibrin were spotted on the surface of the ST316L wire (see
Figure 5.10(a)). Blood cell aggregates or PMPs covered by a thin film of fibrin were
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observed in Figure 5.10(b). Fibrin clots were also present on the TiAl6V4 wire surfaces,
while only a few platelets could be identified on the surface (Figure 5.10(c) and (d)).
(a) (b)
(c) (d)
Figure 5.10: Cell adhesion and fibrin deposition on metal wires at 100 s−1. (a) and (b)
ST316L wire, (c) and (d) TiAl6V4 wire.
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Under shear rate of 500 s−1
Low magnification Figure 5.11(a) shows the detached fibrin tethers on ST316L wires.
Leukocyte-platelet aggregates were assumed to be involved in the cell adhesion process,
as activated platelets and leukocytes were observed in the black square of Figure 5.11(b).
Moreover, a few leukocytes in Figure 5.11(c) were also found embedded or fully covered
by a thin layer of fibrin. These findings suggest that leukocytes were also involved in the
blood clot formation under flow conditions. Figure 5.11(d) shows the protein deposition,
fibrin tethers, and possibly some PMPs on the ST316L wire surface.
Long protein fibers were present on the TiAl6V4 wires. The fiber in Figure 5.11(e) had
a length of more than 1 mm. Higher magnification images show that the long fiber was
composed of small fibrin fibers, red blood cells and platelets. Abundant platelets and PMPs






Figure 5.11: Blood cell adhesion on ST316L ((a) to (d)) and TiAl6V4 ((e) and (f)) wires
at 500 s−1, (a) Detached fibrin tethers, (b) Leukocyte-plaltelet aggregates adhesion, (c)
Blood cells covered by protein, (d) Platelet and PMP adhesion on fibrin, (e) Blood cells
embedded in long fibers, (f) Platelets and PMPs aggregates.
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Under shear rate of 1500 s−1
Generally, blood cell adhesion and protein adsorption at 1500 s−1 remained at a very
low level on both metal wire surfaces. Only a few fibrin fibers were observed on ST316L
wire surfaces (Figure 5.12(a) and (b)), with little blood cell adhesion. Small tethers were
noticed on TiAl6V4 wire surfaces as shown in Figure 5.12(c), and a few platelets were
found adhering to the surface (Figure 5.12(d)).
(a) (b)
(c) (d)
Figure 5.12: Cell adhesion and fibrin deposition on metal wires at 1500 s−1. (a) and (b)
ST316L wire, (c) and (d) TiAl6V4 wire.
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5.4.5 Cell adhesion in flow system
Silicone sheets in the flow chamber were also collected and analyzed by SEM. The sili-
cone sheets from different samples presented similar surface morphology. Fibrin and large
amount of particles were attached. These particles had irregular shape and various size,
and may be small pieces of fibrin, cell debris and their aggregates. Representative images




Figure 5.13: Surface morphology of silicone sheets in flow chambers after recirculation with
(a) TiAl6V4 wire blood sample, (b) No wire blood sample, (c) SFLLRN activated blood
sample, (d) EDTA inhibited blood sample. The arrow in the figure indicates direction of




6.1 Blood Circulation Model
In the study with the Master Flex peristaltic pump, red blood cell lysis occurred after two-
hour recirculation. Clinical studies have reported that roller pumps can cause bleeding and
hypotension from pump-induced platelet activation [96, 97]. Mechanical damage to blood
cells was also noticed after in vitro blood circulation with the roller pump [98–102]. Rollers
or impellers were suspected to crush blood cells and cause red blood cell lysis during blood
circulation. It is thought that potential mechanical damage on platelets may have resulted
in smaller average platelet size and less CD61 expression on each platelet. The latter
was one of the observations made following the use of the peristaltic pump. Meanwhile,
more PMPs might be shed during recirculation; these may bind to leukocytes and form
aggregates further increasing the level of blood activation.
Hemoglobin is released into plasma either after red blood cell membrane rupture [103],
or through the pores of a thinned membrane as a result of mechanical stress [100]. This
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will lead to the red appearance of plasma. This was confirmed by a previous study in which
researchers found a 2% hemolysis after two hour circulation with a roller pump [104].
Red blood cell fragments generated by the use of a roller pump has been reported
previously. Linneweber et al. showed a tenfold fragments increase after a blood sample
was circulated in a roller pump for two hours [101]. Blood viscosity may also increase due
to the red blood cell aggregates and their fragments [105]. Moreover, the size distribution
of red blood cell fragments is very close to that of intact platelets [99], and this could
potentially affect the proper detection of platelets by flow cytometry.
Changes in roller pump parameters, such as impeller speed, flow rate, and tip gap,
can affect the degree of hemolysis. It has been shown that blood damage increases with
circulation time and impeller speed, as well as decreased flow rate [106]. Another potential
drawback of the MasterFlex pump was that it only had two channels, and therefore did
not meet the requirements of the simultaneous multiple-sample test for this study. The
peristaltic pump circulation model was thus not adopted in later experiments.
6.2 Blood Cell Activation Under Static Conditions
6.2.1 Platelet activation
Blood-material contact can induce platelet activation and subsequent platelet microparticle
shedding. In the static experiments, the platelet activation and adhesion of ST316L were
higher than TiAl6V4, which may be primarily because of the difference of metal surface
properties, including chemical composition and surface topography.
Platelet activation in both whole blood and PRP was also lower with TiAl6V4 disks
than the negative controls (Rest0 and Rest2hr) and other test materials, as shown by the
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reduced CD61 expression on platelets. This surprising result was in accordance with a pre-
vious study by Takami et al. [107], in which platelets in heparinized blood incubated with
TiAl6V4 rod for three hours had a lower (although not statistically significant) P-selectin
expression compared to their negative control (0 hour). It is known that procoagulant
microparticles can mediate cell interaction through P-selectin [108] and bind to activated
platelets and leukocytes, leading to both a decrease in PMPs in blood and reduced CD61
expression on platelets. The reduced CD61 expression on platelet microparticles with
TiAl6V4 may thus be due to an increase in microparticle shedding, which then bind to
leukocytes and are thus not sorted as PMPs. However, the presence of leukocyte-platelet
aggregates did not increase with TiAl6V4, negating this hypothesis. The reduced CD61
expression may indicate that platelet activation in TiAl6V4 is suppressed because of higher
albumin/fibrinogen ratio on TiAl6V4 surface. Albumin adsorption happens earlier than
fibrinogen, and albumin adsorption being favored on the TiAl6V4 surface would then pro-
vide a more platelet-biocompatible surface and reduce platelet activation [109].
The static condition results showing higher platelet activation with ST316L compared
to TiAl6V4 agree with published in vitro studies that indicat higher platelet activation
with ST316L relative to other biomaterials [110, 111]. Increased platelet adhesion and
aggregation were also found on ST316L compared to diamond like carbon (DLC) coated
surface [112]. The chemical composition of ST316L is actually believed to play a key
role in platelet activation. It has been reported that after blood contact with ST316L,
GPIIb/IIIa receptors stored inside the platelet translocate to the platelet membrane and
are more active than surface ones by displaying higher affinity towards anti-CD61 antibody
and promoting higher levels of platelet adhesion and aggregation on biomaterials. Silicone
and ST316L have also been shown to produce approximately the same levels of thrombin-
antithrombin complex and complement C3a expression [113], which would agree with the
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experimental data of this study whereby silicone and ST316L induced similar levels of
platelet and leukocyte activation in the static experiments.
Blood incubation with polystyrene was used to create somewhat of a positive control
material in the static test. However, bulk platelet activation was not significant after 2
hrs. Ye et al. had previously shown that protein adsorption and platelet adhesion on
polystyrene was significantly higher than TiAl6V4 which may have suggested a higher
platelet activation in the bulk, especially since platelet activation as measured by annexin V
expression was also reported to be higher than TiAl6V4 [114]. Taken together, these studies
and the current results from platelet activation and adhesion on the surfaces would tend to
suggest that platelet activation in the bulk may not be observed despite significant platelet
adhesion on a biomaterial. Such results further highlight the importance of studying what
happens on the surface of a biomaterial and what remains in the flowing blood when testing
material biocompatibility.
While these results have been discussed related to material-induced activation, it is also
important to note that the blood collection protocol may also partially have contributed
to the slight platelet activation in Rest0. In platelet activation studies, some researchers
discard the first 1-3 ml blood, because it contains activated platelets caused by blood
vessel injury and blood contacting with the syringe surface. In this study, blood was
drawn without discarding the first milliliter. The anticoagulant heparin has also been
reported to potentiate platelet aggregation and conformational change [115], which may
explain the observation of higher values in the Rest0 sample. As mentioned previously,
similar results at time 0 have also been noted by Takami et al. [107].
The overall PMP formation in the static experiments can be considered negligible. The
inability to record changes in microparticle platelet formation may be due to how platelet
microparticles were identified. Empirically gating [116,117] (preferred method) and beads
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calibration [118] are both used in identifying PMPs. However, the average platelet size is
different between blood donors, likewise, the average size of their PMPs is different. In the
current study, the average platelet size was first measured according to the median FSC
value of gated platelets, then set the PMP limit to the 35% of the average platelet size, thus
we may have not been able to record small change in platelet microparticle formation. It is
also very likely that under the current experimental conditions (static), material-induced
platelet activation is too low and thus platelets will not shed microparticles due to a lack of
stimulation. Previous studies with metal discs have mostly focused on adhesion and thus
there was little data available on measuring platelet activation in the bulk under static
conditions. The low level of platelet microparticle formation compares well with those
observed in Park et al.’s work using smooth disks [10]. However, it was surprising to see
that increase contact time with the biomaterial did not increase microparticle formation:
similar experimental conditions were used except incubation time was 30 min in their study
while contact time was increased to 2hrs to observe the potential expression of TF.
6.2.2 Leukocyte activation
Under static conditions, CD11b upregulation is mainly dependent on the blood-material
contact [53,119]. While we were unable to detect platelet activation, leukocyte activation,
as measured by CD11b upregulation, occurred with biomaterial samples. Material-induced
leukocyte activation was most likely mediated by both soluble fibrinogen [56] and soluble
complement factors C5a [119–121] and further experiments will be required to specifically
determine the mechanisms of material-induced CD11b upregulation under static condi-
tions.
While it was observed that some material-induced CD11b upregulation occurred, the
difference was not statistically significant compared to the negative control (Rest2hr).
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Smooth annealing treated Titanium surface has been shown to be more biocompatible
than acid-roughed titanium surface [122] and this may explain the lack of statistical signif-
icance in the current results as only annealed titanium disks were tested. Acid-treatment of
the titanium surface may help in further determining the sensitivity of the static model for
leukocyte activation. It is also possible that more activated leukocytes were lost through
adhesion on the material since besides upregulation, CD11b also undergoes a qualitative
change [123] which further promotes cell aggregation and adhesion. There is also evi-
dence from previous work with polymers that leukocyte activation is strongly dependent
on surface area [53] and under the static experiment conditions, a similar surface area with
polymer would also not have induced statistically significant leukocyte activation.
Monocyte-platelet aggregates can be viewed as a marker for both platelet and leukocyte
activation. Similarly to the current results, higher CD61 intensities are commonly observed
with monocytes since they are more sensitive to activated platelets and microparticles than
neutrophils [47, 124]. Leukocyte-platelet aggregate formation is dependent on activated
platelets but also on PMPs which serve as bridge between leukocytes [108]. PMPs have
actually been shown to be more effective than platelets in bridging leukocytes [125]. Since
both a low PMP level and low platelet activation were observed, it is not surprising that
leukocyte-platelet aggregate formation remained low under static conditions.
A strong correlation has been found between platelet activation, monocyte-platelet ag-
gregate formation and TF expression [126] and thus the low TF expression results are in
accordance with the overall level of blood activation in the samples. It is also important to
note that the absence of TF expression following biomaterial contact is indirect evidence
that the biomaterials were endotoxin-free as any endotoxin contamination of the biomate-




Under static conditions, we were able to observe differences in blood cell adhesion between
the two metal biomaterials tested. These results are in agreement with previous work by
Takami et al. [107] and Tanaka et al. [61] who showed that the composition of the metal
disk surfaces is one of the main factors determining platelet adhesion. Using up to seven
different metals of similar surface roughness and either qualitative SEM observation or
quantitative optical density measurements of CD61, they observed the effect of metallic
material chemistry on platelet adhesion and fibrin formation.
Increased fibrinogen adsorption and blood cell adhesion was found on the surface of
ST316L disk compared to the TiAL6V4 disks. While such a difference may be due to ma-
terial chemistry, it is important to note that the surface of ST316L may also be rougher. A
roughed material surface can increase surface area, which in turn increases plasma protein
adsorption and subsequent platelet adhesion and activation [10]. Nygren et al. showed
increased fibrinogen adsorption, platelet adhesion and P-selectin expression on the hy-
drofluoric acid-roughed surfaces compared to the smooth machined pure titanium [122].
Hong et al. observed more platelet adhesion on roughed TiN surfaces than smooth TiN
surfaces [127]. Cracks with a depth of about 2 m, were observed on the ST316L surface;
this may have increased the overall surface area onto which proteins can adsorb but it may
also have provided area where blood could be entrapped and create local sites of activation
because of the localized high surface area to blood ratio in the cracks. Fibrinogen has the
potential to promote leukocyte-platelet aggregates. However, considering low P-selectin
expression, the leukocyte adhesion on ST316L disk was most likely mainly mediated by
the interaction between CD11b and GPIIb/IIIa since both are expressed on resting cells.
This was in accordance with a previous study that monocyte adhesion on ST316L was
mediated by CD11b [128].
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Hansi et al. [63] as well as Thierry et al. [72] found platelets strongly adhering to the
surface of bare ST316L with the majority of the attached platelets displaying a dendritic
shape with marked pseudopodia. However, during the incubation with platelet rich plasma
(PRP), most platelets remained discoid or at a lower activation stage, such as dendritic or
dendritic spread. This was in contrast to the blood experiments, where significant platelet
activation and fibrin clots could be observed on the ST316L surface.
Compared to ST316L, low levels of platelets and platelet aggregates were observed on
TiAl6V4 surface; it was also difficult to view if any PMPs were present due to their small
size and the complex surface microtexture of TiAl6V4. Interestingly, despite low adhesion,
the adherent platelets were at a higher activation stages and displayed spread or fully spread
morphological shape compared to ST316L in PRP experiments. When comparing platelet
adhesion on TiAl6V4 and ST316L, contradictory results have been obtained. Minimal
platelet adhesion has been shown on TiAl6V4 compared with other biomaterials [107]
while higher platelet adhesion level on TiAl6V4 than on ST316L was reported by Tanaka
et al. [61]. Such differences in results may come from different experimental conditions
(contact time, anticoagulant concentration, whole blood versus PRP) and material surface
preparation (surface polishing versus none). In Tanaka et al. [61] experiment, shorter
incubation time (20 min) and surface polishing were used. Within short incubation time,
albumin is mainly responsible for blood cell adhesion, as it moves faster than other plasma
proteins. The polishing step with SiC before incubation may also have altered their surface.
In this regard, the titanium oxide film of the metal sample may be thicker and more stable,
and thus lead to better hemocompatibility compared to their TiAl6V4 surface.
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6.3 Blood Cell Activation Under Shear Conditions
6.3.1 Platelet activation
Compared to the static experiments, PMP formation almost doubled that found in the flow
experiments. PMP formation also continued to increase at 6200 s−1 shear rate , further
confirming previous results which showed that platelet activation depends on shear [43,129].
The increase in PMPs formation may come from the shear effect and/or contact with the
in vitro flow system.
While we did observe an increase in PMP formation, there was no significant change
between 100 s−1 , 500 s−1 and 1500 s−1 in the presence or absence of the wires. Thus
physiological shear stress was too low to significantly activate platelets and the presence of
biomaterial did not have an effect at these shear rates. Indeed, previous studies have shown
that compared with the baseline at 10 s−1, significant platelet activation was only observed
at or above 6000 s−1 [87,130]. Performing short studies at 6200 s−1, we further verified that
the in vitro flow chamber model was able to agree with these published results and the lack
of platelet activation was not due to an in vitro flow model that did not perform adequately
but to a lack of material-induced activation. Based on a previous study showing PMP
formation increasing with prolonged time under shear conditions [131], we had initially
hypothesized that 2hrs recirculation with biomaterials would provide enough stimulation
for platelet activation even under low shear conditions but the current results disproved
the hypothesis. The fact that we did not observe any difference in CD61 expression and
microparticle formation between the test materials may be explained by the small surface
area/blood volume ratio. In flow experiments, metal wires with a total surface area of
0.3 cm2 were circulated with more than 1 ml blood. The surface area/blood volume ratio
decreased more than 10 times compared to the static in vitro model. Moreover, syringe,
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sample tube, silicone tubing and sheet had a much larger surface area than the tested stent
material itself. Thus any platelet activation induced by the metal wires was most likely
buried in the background activation of the in vitro flow model. Furthermore, the result
of SFLLRN flow experiments demonstrated that PMP percent gradually decreased during
circulation, suggesting that they may bind to other blood cells, form aggregates and thus
be sorted as cells or further decrease in size and become undetectable by flow cytometry.
The PMP decrease may also be explained by them simply binding to the inner surface of
the in vitro system. It is likely that a combination of these scenarios occurred over time.
6.3.2 Leukocyte activation
Despite a rougher surface, CD11b expression induced by TiAl6V4 wire was generally lower
than ST316L. Under flow conditions, previous studies have reported that leukocyte acti-
vation depended on material surface chemical composition and topography [132] and that
CD11b up-regulation was also sensitive to material surface area [133]. The results would
tend to disagree with such statements and suggest that material chemistry was the most
important factor in material-induced leukocyte activation.
In parallel to increase in platelet activation with an upregulation of P-selectin induced
by shear, leukocyte-platelet aggregates significantly increased compared to the static ex-
periments. This is in agreement with recent studies showing that, under flow conditions,
platelet and leukocyte interaction is mainly through the P-selectin-PSGL-1 rather than
through the complex GPIIb/IIIa-fibrinogen-CD11b [81, 124, 134]. It is also possible that
the in vitro model itself promoted the formation of platelet-leukocytes aggregates as they
tend to form in regions where high shear stress converts to low shear stress [82, 135], or
where pulsatile flow applies [136]. In the in vitro flow model, the inlet and outlet of the
flow chamber were both connected to a silicone tube whose cross sectional area was big-
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ger, resulting in the decrease of shear rate when blood flows out from the chamber; this
configuration rather than shear itself may have contributed to aggregates formation in the
flow experiments.
Leukocyte activation, as measured by CD11b upregulation and platelet-leukocyte ag-
gregates, has been shown to increase with shear stress [81, 124]. However, in the flow
experiments, both CD11b expression and leukocyte-platelet aggregates decreased with in-
creasing shear rate, the latter even in the presence of an increase in platelet activation.
In flow experiments, the blood volume used for each flow condition was 1 ml, 1.7 ml and
3.3 ml to keep the same cycle period and to ensure blood cells have the same number of
passages in contact with the metal wires. With metal wire surface area unchanged but an
increase in blood volume, the decrease of surface area/blood ratio likely may have led to
a ”dilution effect” for leukocyte activation. It is also possible that with increased shear
rate, the cells have less chance to come into contact with the material as the flow rate is
increased and this reduction in contact with the artificial surface may actually explain the
reduced activation in 1500 s−1 compared to 100 s−1.
TF is being recognized as an important player in thrombus formation and fibrin ad-
sorption on artificial surfaces. Platelet activation has been shown to promote TF ex-
pression [17, 126]. In the current experiments, TF expression on monocytes and platelet
activation correlated well at 100 s−1. However as shear increased, despite an increase (al-
beit non significant) in platelet activation, TF expression decreased suggesting that under
higher shear conditions platelet activation may not be able to contribute to TF expression
due to the increase flow rate which may limit the ability of platelets to bind to monocytes.
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6.3.3 Cell adhesion
Fibrin deposition and blood cell adhesion are dependent on material surface properties
and shear stress magnitude [12, 50]. CD11b and TF have also been shown to mediate
blood cell adhesion and fibrin deposition under flow conditions [17]. These results agree
with these previous observations as higher CD11b upregulation and TF expression were
obtained in ST316L blood samples, and correspondingly, more fibrin deposition and blood
cell adhesion were observed on ST316L surfaces.
We were able to demonstrate from the SEM results with 500 s−1 and 1500 s−1 that,
as shown in previous studies [12, 137, 138], fibrin deposition and cell adhesion on material
surfaces decreased with increasing shear stress. However, significant adhesion on metal
wires at 100 s−1 was not observed. This may be because the metal wires used for SEM
analysis was only from one 100 s−1 flow experiment and may not have been a representative
sample of the surfaces.
Cell debris and microparticle adhesion were also noticeable on the silicone sheet in the
flow chamber, further indicating that material-induced adhesion occurred on the in vitro
flow model making it difficult to assess the effect of the metal itself. The microparticle
presence also provided further evidence that PMPs were consumed on the surface, providing
some explanation to the slow disappearance of PMPs in the bulk of SFLLRN activated
blood at 500 s−1. We were unfortunately unable to clearly assess the surface of the silicone
tubing that was used to pump blood in and out of the chamber as its small diameter made
it impossible to properly observe under SEM.
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Chapter 7
Conclusion and Future Work
7.1 Conclusion
Flow cytometry analysis was a reliable technique to assess both platelet and leukocyte
activation in the bulk. SEM was also a valuable tool to qualitatively evaluate cell adhesion
on material surface, but quantitative analysis of the number of platelets and their state of
activation would provide important information on adherent cells and should be considered
in the future.
Static experiments demonstrated that, with both blood and platelet rich plasma, little
platelet activation occurred in the bulk and difference in platelet activation between ma-
terials could only be observed with platelet adhesion on the surfaces. While we did not
always obtain significant differences between our samples, the in vitro flow model using
the parallel plate flow chamber appeared to be a useful platform to study cell activation in
blood under various shear conditions. The presence of shear resulted in increase platelet
activation, but no difference between shear rate and materials was obtained under the
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physiological shear rate conditions tested (100 to 1500 s−1). On the other hand, significant
differences were observed in material-induced leukocyte activation under shear conditions.
At 100 s−1, increase in CD11b upregulation, platelet-leukocyte aggregates and TF expres-
sion was detected. Interestingly as shear increased, material-induced leukocyte activation
decreased either as a consequence of reduced contact time with the surface or because of a
significant reduction in surface area to volume ratio. These results also demonstrate that
TiAl6V4 is in general more blood compatible than ST316L under both static and flow
conditions, and thus stent material should be well considered in new stent design to reduce
the risk of in-stent restenosis. However while material had an effect on blood activation, it
is important to note that there did not seem to be a synergistic or priming effect between
the presence of a foreign material and shear in inducing blood activation. This may be due
to experimental conditions such as the small material surface area tested and future work
is needed.
7.2 Future Work
In the present research, blood was collected from healthy donors with an average age of 30.
As coronary artery disease is less likely to happen in young people, comparing material-
induced blood activation under shear conditions using blood from CAD patients, older or
diabetic people with the blood from healthy donors would provide important information
on how disease may affect material biocompatibility. The difference in blood, such as blood
sugar, cholesterol, lipids and even in blood cells, together with other medical conditions
may result in different blood cell activation under shear conditions. These differences may
help explain the discrepancies that are currently observed in patients on anti-platelets and
anticoagulant therapies.
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The blood collection protocol also should be changed. In the current protocol, a tourni-
quet was applied at proper pressure when taking blood. Platelet activation in blood sample
remains small as it usually takes less than 1 minute to collect the blood. However, as more
blood volume is required to produce higher shear rates, and longer collection time is needed.
This may lead to additional initial platelet activation and make it difficult to determine
the effect of shear and materials on activation.
It was difficult to see any difference in material induced platelet activation under flow
conditions and it is believed that this may be due to the small surface area/blood volume
ratio and the large amount of silicone used in the in vitro flow system. Further experiments
are needed to validate this hypothesis; this would also help elucidate our observations that
leukocyte activation appeared to decrease with increased shear. To increase metal surface
area, metal strips rather than wire can be used. For the in vitro model, the setup should
use minimal amount of silicone tubing; one may also considered designing a new in vitro
flow model to limit the use of silicone tubing.
For materials used in the experiments, material surface properties, such as roughness,
chemical composition, and wettability should be characterized. This would provide valu-
able information on the materials and may help in identifying the important properties in
material-induced activation under shear conditions. Treatments of the surface such as acid
or laser treatment would also provide means to increase surface area.
SEM is limited in estimating the total number of adherent platelets on the surface.
Other methods such as radiolabeling or LDH should be considered. It would also be very
valuable to obtain a blood cell count at the end of each experiment and while there may
be a significant cost involved, options should be evaluated.
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University of Waterloo 
March 17, 2008 
Title of Project: Cellular Mechanisms involved in material-induced thrombosis 
Principal Investigator: Maud Gorbet 
                                     University of Waterloo 
Department of Systems Design Engineering 
519-884-4567 Ext. 32602 
Purpose of Study: 
You have been asked to donate a blood sample for a research project aimed at evaluating how white 
blood cells interact with metallic materials used in cardiovascular devices (e.g.: stents and 
mechanical heart valves).  The current study will use blood from healthy volunteers, who have not 
taken any anti-inflammatory or pain killers in the last 48 hours prior to the donation.  This research 
project will contribute to a better understanding of how, upon contact with a foreign material, white 
blood cells may become activated and participate in the formation of blood clots.  A better 
understanding of cell-material interaction will help in developing novel surface modifications and 
therapeutic approaches to reduce the incidence of clotting complications that can significantly impair 
the quality of life of many patients.   
Procedures Involved in this Study: 
We will require a small sample of blood (10 to 15 ml).  A maximum of 15 minutes of your time will 
be required to fill out the consent form, the medical screening form and take the blood sample.  
Blood will be collected in a syringe from a vein in the arm by a certified phlebotomist (registered 
nurse, or a registered technologist trained in venipuncture).  The blood will then be transferred 
immediately in a tube containing anticoagulants.  If at any point during the blood donation you feel 
uncomfortable, we will remove the needle immediately.  It is your choice if you want to be a regular 
donor for this study or if this is a one time only donation. If you choose to be a regular donor, for 
donor comfort, you will not be asked to donate more than twice a week and/or more than six times in 
a month.  The Red Cross policy for limiting blood donation is a volume of 450mL of blood once every 
two months.  
Personal Benefits of Participation: 
You may not benefit personally from your participation in this study. However, the information 
obtained from this research may directly advance the development of better biomaterials and more 
appropriate targeted treatment strategies for reducing/preventing the occurrence of clotting 
complications with cardiovascular devices. 
Risks associated with participation in the study: 
This is considered a low risk study and minimal risks are anticipated. As with regular blood 
collection procedures for medical purposes, slight pain may be felt upon insertion of the needle in the 
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blood vessel. Small bruising may also occur. The donor may also feel faint when the blood is drawn. 
A fruit juice drink will be available after donating your blood.  
 
Medical Screening Form: 
This questionnaire asks some questions about your health status. This information is used to guide us 
with your entry into the study. Exclusions to participation in this study include any kidney problems 
or any cardiovascular diseases including bleeding disorders and anaemia. 
Changing Your Mind about Participation: 
You may withdraw from this study at any time without penalty. To do so, indicate this to the 
researcher or one of the research assistants by saying, "I no longer wish to donate blood for this 
study". 
Confidentiality: 
To ensure the confidentiality of individuals’ data, each blood donor will be identified by a donor 
identification code known only to the principal investigator and his research assistants.  Blood 
samples will be kept up to a week in the fridge.  Serum or plasma derived from the blood samples 
will be kept up to six months in a -70oC freezer.  All samples derived from the blood experiments 
will be used solely for the purpose of identifying inflammatory and thrombotic factors.   
Contact Information: 
If you have any questions about the study at any time, please contact Professor Maud Gorbet at her 
office 519-888-4567 ext. 32602, or by email at mgorbet@uwaterloo.ca. 
Participant Feedback: 
If you are interested in receiving publications derived from experiments performed with your blood 
donation, you can provide an email address below where we will send you our published studies. 
Concerns about Your Participation 
This study has been reviewed and received ethics clearance through the Office of Research Ethics. 
However, the final decision about participation is yours. If you have any comments or concerns 
resulting from your participation in this study, you may contact the Director, Office of Research 








I agree to take part in a research study being conducted by Dr. Maud Gorbet of the Department of 
Systems Design Engineering, University of Waterloo. 
I have made this decision based on the information I have read in the Information letter. All the 
procedures, any risks and benefits have been explained to me. I have had the opportunity to ask any 
questions and to receive any additional details I wanted about the study. If I have questions later 
about the study, I can ask the principal investigator Maud Gorbet (SYDE, 519-888-4567 x32602). 
 [  ] I agree to be a one-time only donor for the study. 
[  ] I agree to be a regular donor for the study.  I will not be asked to donate more than twice a week 
and/or more than six times in a month.  
I understand that I may withdraw from the study at any time without penalty by telling the 
researcher.  
[  ]  I wish to receive research publications on experiments that used my donated blood. 
Email address:   _______________________________ 
  
This project has been reviewed by, and received ethics clearance through, the Office of Research 
Ethics at the University of Waterloo. I am aware that I may contact this office (519-888-4567, ext. 
36005) if I have any concerns or questions resulting from my involvement in this study. 
_______________________________                    ___________________________________ 
Printed Name of Participant                                       Signature of Participant 
 
_______________________________                    ___________________________________ 








HEALTH SCREENING FORM 
STUDY: Cellular Mechanisms involved in material-induced thrombosis 
Name: 
______________________________________________________________________________ 
Phone # (optional):  ________________________ Year of Birth: _________________  
 
SELF REPORT CHECKLIST: 
Known Health Problems (check appropriate): 
[ ] Anaemia – Low red blood cell count  
[ ] Rheumatic Fever                
[ ] Epilepsy 
[ ] Heart Murmur                    
[ ] Emphysema, Pneumonia,Bronchitis 
[ ] High Blood Pressure          
[ ] Disease of the Arteries 
[ ] Congenital Heart Disease    









[ ] Heart Attack                     
[ ] Heart Operation 
[ ] Kidney and liver disease      
[ ] Diabetes (diet or insulin)      
[ ] Enteritis/Colitis/Diverticulitis 
[ ] Ulcers                               
[ ] Bleeding from Intestinal Tract 
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